Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2024-09-08 Director's Dealing
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 233.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including dates, number of shares/options acquired, and nature of the interest. This is a report of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document length is 3390 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the correct classification is DIRS (Director's Dealing).
2024-09-08 English
Preliminary Final Report 36 pages 964.2KB
Annual Report Classification · 95% confidence The document is titled 'ASX Preliminary final report – 30 June 2024' and contains detailed financial statements including a consolidated statement of profit or loss, statement of financial position, statement of changes in equity, and cash flows for the year ended 30 June 2024. It includes comprehensive financial data such as revenue, EBITDA, net loss, segment revenue breakdowns, and notes to the financial statements. The document also discusses operational reviews, outlook, and dividend information. The length is substantial (15,000 characters) and it is not merely an announcement or a certification. The content matches the characteristics of an Annual Report or a full year financial report. Given the Australian context and the detailed full-year financial data, this corresponds to an Annual Report (10-K equivalent). FY 2024
2024-08-27 English
FY24 Preliminary Report and FY25 Guidance 2 pages 142.6KB
Earnings Release Classification · 95% confidence The document is titled 'FY24 Preliminary Report and FY25 Guidance' and provides unaudited financial results for the fiscal year ended 30 June 2024, including revenue, EBITDA, cash flow, and guidance for FY25. It is a summary of financial performance and outlook rather than a full annual report. The document length is 2970 characters, which is relatively short and consistent with an earnings release rather than a comprehensive annual report. It includes key financial highlights and forward-looking guidance, typical of an Earnings Release (ER). There is no indication that this is a full Annual Report (10-K) or an Audit Report (AR). It is not a report publication announcement (RPA) because it contains substantive financial data, not just a notice of report availability. Therefore, the document is best classified as an Earnings Release (ER). FY 2024
2024-08-27 English
Investor Presentation 19 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation Full Year 2024 Results August 2024' and contains detailed financial data including revenue, EBITDA, profit and loss summary, balance sheet, cash flow summary, and FY25 outlook. It includes forward-looking statements, operational updates, capital raise information, and strategic priorities. The document is structured as a presentation with slides and charts summarizing the company's full year financial results and outlook for the next fiscal year. It is not a full annual report (10-K) but a detailed presentation aimed at investors summarizing the financial performance and strategy. Therefore, it fits the definition of an Investor Presentation (IP). The document length (11,479 characters) and content confirm it is the presentation itself, not just an announcement or a brief summary.
2024-08-27 English
FY24 full year results investor conference call details 1
Report Publication Announcement Classification · 95% confidence The document is a short announcement dated 21 August 2024 about SomnoMed's upcoming FY2024 full-year financial results release and an investor conference call scheduled for 28 August 2024. It provides details on how to register for the call and webcast but does not contain any actual financial data or detailed financial statements. The document explicitly states that the financial results and investor presentation will be released on a future date, indicating this is a notice or announcement rather than the report itself. The length is only 2052 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document fits the criteria for a Report Publication Announcement (RPA) rather than an Annual Report (10-K), Earnings Release (ER), or Investor Presentation (IP).
2024-08-20 English
Quarterly Activities Report 4 pages 286.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report and Company Update' and provides detailed financial data for the quarter ended 30 June 2024 (Q4 FY24) and the full fiscal year FY24. It includes unaudited revenue figures, EBITDA guidance, cash balances, operational comments, and a financial review with segmented revenue data. The document also discusses management changes and operational updates. The length is 6874 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. The presence of detailed quarterly financial results and operational commentary aligns with the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement of a report or a certification, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is IR (Interim / Quarterly Report). Q4 2024
2024-07-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.